To collect quantitative data to: -Primarily gain a better understanding of patients' attitudes and preferences regarding end-of-life care management if they were to develop a high-risk skin cancer. To be more specific, we hope to gain a better understanding of how patients weigh their risk of developing skin cancer while taking immunosuppressants versus the risk of transplant rejection should they choose to stop or lower their immunosuppressants. -Determine how far these kidney transplant recipients travel to obtain skin-related care -Determine how frequently kidney transplant recipients obtain skin exams -Determine patients' baseline knowledge regarding risk of skin cancer while taking immunosuppressants, which are medicines that lowers immune systems -Determine the quality of life of individuals with skin cancer who are kidney transplant recipients

Belatacept is a drug that helps kidney transplant recipients by preventing the body from rejecting the new organ. We want to compare how well belatacept works compared to the commonly used drug tacrolimus. To do this, we plan to study people who got kidney transplants in the United States from 2011 to 2020. By using two large databases, the United States Renal Data System, and the Scientific Registry of Transplant Recipients, we aim to understand how belatacept is used in real life. We are also interested in comparing how effective and safe is belatacept compared with tacrolimus after one year of administration. We will look at outcomes like how long the transplanted kidney will work, how long will the kidney transplant recipients live, how well your kidneys will work, the risk of organ rejection, and certain side effects to happen after transplant like blood cancer.

The goal of this study is to determine which treatment option is best to start with for patients with Severe Aplastic Anemia (SAA), between a matched unrelated donor bone marrow transplant or immune suppressive therapy, when a matched related donor is not available.

This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications. This protocol will allow access to cord blood units that are unlicensed.

The purpose of this registry is to observe outcomes of heart transplant recipients who are managed with HeartCare. This is done by collecting information about your heart transplant such as test results, biopsy results, and outcomes, storing that information in a database, and using that information for research.

This study will evaluate the use of MMUD PBSC in adults and explore the safety and efficacy of MMUD BM in pediatric recipients with hematological malignancies who may lack other donor options.

The purpose of this study is to collect data from patients, caregivers, and VAD coordinators to ascertain the stressors associated with having a Ventricular Assist Device (VAD) and use that data to create support groups.

The mission of the Collaborative Islet Transplant Registry (CITR) is to expedite progress and promote safety in islet/beta cell transplantation through the collection, analysis, and communication of comprehensive and current data on all islet/beta cell transplants performed in North America, Europe and Australia.

This study explores how religious beliefs influence decisions about organ donation in Black Christian communities. Many Black Americans need organ transplants, but donation rates in these communities are lower than in others. Religious beliefs may play a role in these decisions, but past research has not fully explored how people learn about their religion's views on organ donation or how these beliefs affect their choices. By interviewing Black Christians, this study aims to better understand their thoughts, experiences, and concerns about organ donation. The goal is to help create better ways to share information about organ donation that respect religious beliefs and encourage informed decision-making.